Literature DB >> 2112257

Motor performance decrement by midazolam: antagonism by Ro 15-1788 and CGS 8216.

C E Lau1, J L Falk, M Tang.   

Abstract

Rats were trained in a fine motor control performance that required operation by a paw of a force transducer so that it remained between upper and lower limits of a force band for a continuous 1.5-sec period to deliver each food pellet. Acute doses of midazolam (0.75-3.0 mg/kg, SC) impaired indices of motor performance in a graded, dose-related fashion. When administered alone, Ro 15-1788 (0.1-5.0 mg/kg, SC) had no effect on motor behavior while CGS 8216 (0.5 and 1.0 mg/kg, IP) alone had small effects. In general, the motor performance decrements produced by midazolam were antagonized in a dose-related fashion by both Ro 15-1788 and CGS 8216.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112257     DOI: 10.1016/0091-3057(90)90139-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  Dissociation between the effects of benzodiazepine receptor agonists on behavioral vigilance and responsitivity.

Authors:  P Dudchenko; B Paul; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics.

Authors:  C E Lau; F Ma; Y Wang; C Smith
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

3.  Low and high doses of midazolam differentially affect hypoalgesia in rats conditioned to a heat stressor.

Authors:  J A Harris; I S McGregor; R F Westbrook
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Effects of midazolam and naloxone in rats tested for sensitivity/reactivity to formalin pain in a familiar, novel or aversively conditioned environment.

Authors:  J A Harris; R F Westbrook
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.